Catalyst Biosciences Inc (NASDAQ: CBIO) has reported E.P.S. of $-1.41 for its fourth fiscal quarter (ending December 31) versus $-1.27 for the same period a year ago. E.P.S. were $-1.41 for the latest four quarters through December 31 versus $-0.26 for the same period a year ago.
Recent Price Action
On 3/26/24, Catalyst Biosciences Inc (NASDAQ: CBIO) stock enjoyed a large increase of 3.8%, closing at $16.79. However, below average trading volume at 81% of normal accompanied the advance. The stock has been exceptionally strong relative to the market over the last nine months but has declined -7.5% during the last week.
Current PriceTarget Research Rating
CBIO’s future returns on capital are forecasted to be below the cost of capital. Accordingly, the company is expected to be a major Value Eraser.
Catalyst Biosciences is currently unrated.
Rating Review
The stock is currently unrated.
Be the first to comment